The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
With thousands of press releases published each week, it can be difficult to keep up with everything on . To help healthcare ...
The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...
Zacks.com on MSN2d
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on UpdatesIt was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and ...
The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...
Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback